| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |